Research
& Publications

Explores functional, affective, sleep, and quality-of-life outcomes following EEG-spectra-guided PrTMS in a 73-year-old patient experiencing age-related cognitive changes, demonstrating substantial improvements in perceived cognitive function, mood, anxiety, and sleep.

Examines rTMS treatment of recurrent MDD and GAD in a patient with atrial fibrillation, demonstrating a 55% reduction in PHQ-9 scores and 22.2% reduction in GAD-7 scores, marking the first study demonstrating safety and efficacy of figure-8 coil rTMS at 10 Hz in MDD comorbid with AF.

Underscores the feasibility of transcranial photobiomodulation (tPBM) as a maintenance strategy following an acute rTMS course for treatment-resistant MDD and GAD, with all three patients sustaining clinical response over approximately 6 months post-rTMS.

Examines rTMS for recurrent MDD and GAD in a patient with Thalamic Pain Syndrome, achieving a 95.5% reduction in PHQ-9 scores and 88.2% reduction in GAD-7 scores, with notable improvement in neuropathic pain symptoms and quality of life.

Explores rTMS therapeutic outcomes in a patient with recurrent MDD and GAD comorbid with multiple co-occurring systemic diseases—heart failure, renal disease, type 2 diabetes, and HIV—achieving more than 50% symptom reduction by week 5 and more than 80% improvement from week 6 onward.

Evaluates PrTMS therapeutic outcomes in three pediatric patients with autism spectrum disorder over six weeks, showing an average reduction of 7.5 points in CARS scores and 9-point reduction in ADHD symptoms as measured by the NICHQ Vanderbilt Assessment Scale.

Provides evidence demonstrating the beneficial effects of PrTMS coupled with tPBM in treating co-occurring TBI and PTSD in a 28-year-old male, achieving a 64.29% reduction in GAD-7, 50% decrease in PHQ-9, 74.07% reduction in NSI, and 68.63% decrease in PCL-5 scores.

Explores therapeutic outcomes of PrTMS in two PTSD patients with co-occurring psychiatric disorders, using spectral EEG-guided alpha brainwave optimization. PCL-5 scores showed an average reduction of 20.5 points by treatment midpoint, while GAD-7 and PHQ-9 decreased by 7 and 8.5 points, respectively.

Open-label pilot study of PrTMS in 123 ABA-treated autism spectrum condition persons, demonstrating that 44% of subjects had ASC scale scores reduced below diagnostic cutoffs, with spectral EEG regression flattening implying a more balanced E/I ratio.

Comprehensive review of dopamine dysregulation in autism spectrum disorder, summarizing genetic and epigenetic alterations, disrupted mesolimbic reward pathways, and proposing a multi-level framework organizing ASD pathogenesis from genetic changes through to neurocognitive and social behavioral manifestations.

Exploring gene-based therapeutic strategies for Reward Deficiency Syndrome and its implication in addiction treatment, proposing new pathways for intervention.

Analyzing the clinical utility of GARS in diagnosing and treating Reward Deficiency Syndrome, offering a precision medicine approach to improved patient care.

A comprehensive study on the efficacy of personalized rTMS protocols in treating concussive symptoms with EEG guidance, demonstrating significant improvements in patient outcomes.

Pilot clinical data showing positive therapeutic outcomes for concussion using PrTMS guided by spectral EEG, demonstrating the modality's efficacy in restoring alpha oscillatory synchrony and improving cognitive function in concussion patients.

Examines the effects of PrTMS in treatment-resistant PTSD among military combat veterans, demonstrating statistically significant improvements in PTSD symptoms, anxiety, and depression through spectral EEG-guided personalized neuromodulation protocols.

A critical analysis of the economic burden of neuro-psychiatric disorders on a global scale, highlighting the cost-effectiveness of early intervention.

Investigating the potential of Dopamine D2 Agonist Therapy in treating various psychiatric conditions, emphasizing mechanism of action and clinical response.

Presents pilot clinical data on PrTMS guided by EEG spectra for the treatment of concussion, highlighting improvements in cognitive function, mood, and sleep quality through personalized neuromodulation protocols.